Thursday, November 09, 2006

Pharma abandons blockbuster for niche drugs, claims report

I just love the term "niche-buster"...

08/11/2006 - According to a new report, drug makers are shifting to ‘niche-buster’ drugs in an attempt to drive future sales growth. The niche-buster drug has become a viable alternative to the blockbuster drug model that has served the industry so well.

“The industry is turning increasingly to a niche-buster strategy by utilising increased licensing, R&D collaborations and small-scale M&A deals to harness innovation and provide access to markets with high unmet need,” said Datamonitor healthcare strategy analyst Dr. Mark Belsey.
With this switch from blockbuster to niche-buster, the dynamics of R&D activity and company strategy are changing. With greater focus on niche drugs, the industry is becoming increasingly R&D focused.

link to full article

1 comment:

Danny Haszard said...

My issue is Zyprexa which is only FDA approved for schizophrenia (.5-1% of pop) and some bipolar (2% pop) and then an even smaller percentage of theses two groups.
So how does Zyprexa get to be the 7th largest drug sale in the world?

Eli Lilly is in deep trouble for using their drug reps to 'encourage' doctors to write zyprexa for non-FDA approved 'off label' uses.

The drug causes increased diabetes risk,and medicare picks up all the expensive fallout.There are now 7 states (and counting) going after Lilly for fraud and restitution.

--
Daniel Haszard